In a small randomized trial of 51 people with mild cognitive impairment or early dementia due to Alzheimer’s disease, 20 weeks of a very intensive lifestyle program was linked to better clinical ratings on three of four main measures, with the fourth borderline, while a usual-care group got worse on all four.[1] It is a promising early signal, not a treatment, and the program was far more demanding than most people could copy at home.
The trial came up in an October 31, 2026 Natural Awakenings interview with neurologist David Perlmutter, who named it among the studies behind his book Brain Defenders. He argues that Alzheimer’s is driven by more than one pathway and that prevention has to start “upstream.”[2] That is his view. Here is what the trial itself showed.
What the researchers did
Dean Ornish and colleagues enrolled adults aged 45 to 90 with mild cognitive impairment or early dementia due to Alzheimer’s and a Montreal Cognitive Assessment score of 18 or higher. Mean age was 73.5. Half were assigned to the intervention and half to a wait-list usual-care group.[1]
The intervention had four parts:
- A whole-foods, plant-based (vegan) diet with roughly 14 to 18 percent of calories from fat. Calories were not restricted, and meals and supplements were shipped to participants and their spouse or study partner twice a week.[1]
- At least 30 minutes of aerobic exercise a day plus mild strength training at least three times a week.[1]
- About an hour a day of meditation, gentle yoga-based poses, stretching and breathing exercises.[1]
- Support-group sessions for participants and their partners.[1]
What it found
After 20 weeks, the groups differed on three of the four main measures: the Clinical Global Impression of Change (p = 0.001), the Clinical Dementia Rating Sum of Boxes (p = 0.032) and the Clinical Dementia Rating Global score (p = 0.037). The ADAS-Cog cognition test was borderline (p = 0.053). The intervention group improved or progressed less, and the control group worsened on all four.[1]
A blood marker linked to amyloid, the plasma Aβ42/40 ratio, rose in the intervention group and fell in the control group (p = 0.003). The gut microbiome changed only in the intervention group.[1] Both are surrogate markers, meaning they stand in for what happens in the brain rather than measuring it.
Why the result needs caution
- It is small. Only 51 people were randomized, and the authors note the sample had less racial and ethnic diversity than they wanted.[1]
- It is short. Twenty weeks is brief for a condition that unfolds over years, and the trial did not measure brain structure directly.[1]
- Participants could not be blinded to which group they were in, which can influence how people perform and report. Raters were blinded.[1]
- The trial was registered retrospectively, in October 2020, after it began.[1]
- Two people withdrew.[1]
- Funding and disclosures: the trial was funded by philanthropic donors and foundations, and the paper reports that some authors, including Ornish, have consulted for Sharecare and received book royalties and lecture honoraria.[1]
- The package is bundled, so the trial cannot say whether the diet, the exercise, the stress work or the social support did the work.
What to do with this
Don’t change an Alzheimer’s treatment plan without talking to your clinician first. These pieces are common habits, but this trial tested them as a treatment program in people who already had cognitive impairment, not as prevention, so it does not show they would stop or delay Alzheimer’s in anyone else. Check with a clinician before starting a vigorous exercise or diet change. If memory changes are worrying you or someone close to you, ask a clinician about an evaluation. Perlmutter says the disease may start decades before memory fails, which is his view, not a trial result.[2]
- Ask your clinician whether any piece fits you.
- Bring a family member or friend into the plan. The trial included spouses or study partners.
- Before a major diet change, check with your doctor, especially if you take medication or have a health condition.
References
[1] Ornish D, Madison C, Kivipelto M, Kemp C, et al. Effects of intensive lifestyle changes on the progression of mild cognitive impairment or early dementia due to Alzheimer’s disease: a randomized, controlled clinical trial. Alzheimer’s Research & Therapy, 2024;16:122. PMID 38849944. Population: 51 adults aged 45 to 90, mean age 73.5, 20 weeks. DOI: https://doi.org/10.1186/s13195-024-01482-z. Finding as used: significant between-group differences on CGIC (p = 0.001), CDR-SB (p = 0.032) and CDR Global (p = 0.037), borderline on ADAS-Cog (p = 0.053); plasma Aβ42/40 ratio p = 0.003; small sample, short duration, unblinded participants (NCT04606420). ↑︎ a b c d e f g h i j k l m n
[2] Yeyati S. Blueprint for Alzheimer’s Prevention (interview with David Perlmutter). Natural Awakenings, November 2026 issue, October 31, 2026. URL: https://www.naturalawakenings.com/2026/10/31/perlmutterww. Used only for Perlmutter’s stated views, which are an expert interview and not trial evidence. ↑︎ a b

Kurt Greiner
Kurt is a digital strategist and IT professional blending emerging technology with practical application, exploring how individuals can leverage modern tools to navigate the second half of life with purpose.

Leave a Reply